Elecsys® Total -Tau CSF
Robust and accurate biomarker tests to solve clinical questions

Robust and accurate biomarker tests to solve clinical questions
Elecsys® Total-Tau CSF (tTau) is an in vitro diagnostic immunoassay intended for the quantitative determination of the total tau protein concentration in human cerebrospinal fluid (CSF).1
Elecsys® tTau assay is part of the Elecsys® AD portfolio, along with Elecsys® β-Amyloid(1-42) CSF II (AB42 2) and Elecsys® Phospho-Tau (181P) CSF (pTau) immunoassays.1
Elecsys® AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.2,3
Elecsys® AD CSF assays enable timely intervention by identifying patients with MCI at risk of progression to AD.1,3

The Power of Elecsys® in Alzheimer’s disease
Robust, clinically validated results to help ensure patients get the care they deserve
References
- Elecsys® Method Sheet: ms_08821941500V1.0, ms_08821909500V1.0, ms_08846715500V1.0, ms_08846693500V1.0, ms_08846634500V1.0, ms_08846685500V1.0
- Rabinovici, G.D. et al. (2019). Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 321(13), 1286-1294.
- Hansson, O. et al. (2018). CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14(11), 1470-1481